Quality issues at Sanofi’s beleaguered API spinout triggers guidance revision
2024-03-15
高管变更并购
According to EuroAPI, an internal audit discovered “quality-control deficiencies due to potential local misconduct” at the site, which is responsible for the production of 11 APIs and intermediates comprising mostly anti-infectives.
The quality issue is the latest in a series of setbacks for the API company. In October, EuroAPI trimmed its full-year outlook, citing lower sales volumes and less demand from biotech clients.
During its quarterly earnings report in February, EuroAPI announced a four-year plan to boost profitability by streamlining its product portfolio, as well as the appointment of new chief executive Ludwig de Mot to guide the transition. He succeeds Viviane Monges, who has served as interim CEO since October, when she took the reins from founding CEO Karl Rotthier.
The API production company brought in just over €1 billion in net sales last year; the Brindisi site was responsible for about €63 million. Sales were up 3.8% from 2022 levels, less than half its originally predicted 8% growth.
Sanofi originally announced the creation of EuroAPI in 2021 as a standalone entity that combines the French drugmaker’s commercial and development activities with six of its European production sites to offer a broad portfolio of 200 APIs. The company went on to make its public debut in 2022 on the Paris stock exchange.
Shares of EuroAPI fell more than 17% on Friday to close at €2.7, which is more than 77% below its trading debut price of €12.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。